Published in J Immunol on August 01, 1974
Sex hormones, immune responses, and autoimmune diseases. Mechanisms of sex hormone action. Am J Pathol (1985) 3.31
Sex hormone regulation of in vitro immune response. Estradiol enhances human B cell maturation via inhibition of suppressor T cells in pokeweed mitogen-stimulated cultures. J Exp Med (1981) 1.31
Prenatal exposure to bisphenol A up-regulates immune responses, including T helper 1 and T helper 2 responses, in mice. Immunology (2004) 1.14
Immunosuppression by sex steroid hormones. The effect upon PHA- and PPD-stimulated lymphocytes. Clin Exp Immunol (1977) 1.09
Immunosuppression by human placenta lactogen (HPL) and the pregnancy-specific beta 1-glycoprotein (SP-1). Inhibition of mitogen-induced lymphocyte transformation. Arch Gynakol (1977) 1.00
Effects of bisphenol A on antigen-specific antibody production, proliferative responses of lymphoid cells, and TH1 and TH2 immune responses in mice. Br J Pharmacol (2003) 0.98
Inhibition of human lymphocyte stimulation by steroid hormones: cytokinetic mechanisms. Clin Exp Immunol (1977) 0.98
Distribution of mononuclear cells during pregnancy. Clin Exp Immunol (1978) 0.91
The choice of estrogen preparations in the treatment of prostatic cancer. Can Med Assoc J (1975) 0.84
Thymic involution in pregnant mice. II. Functional aspects of the remaining thymocytes. Clin Exp Immunol (1981) 0.80
Modulatory effects of oestrogen on immunological responsiveness. II. Suppression of tumour-associated immunity in patients with prostatic cancer. Clin Exp Immunol (1979) 0.79
Possible suppression of host resistance by estrogen therapy for prostatic cancer. Can Med Assoc J (1976) 0.75
Carcinoembryonic antigen in patients with different cancers. JAMA (1972) 2.56
Aetiology of Kaposi's sarcoma. Lancet (1990) 1.95
Tissue- and species-specific antigens of normal human prostatic tissue. J Immunol (1970) 1.22
Involvement of the genitourinary system in multiple primary malignant neoplasms: a review. J Clin Oncol (1983) 1.18
Remission of metastatic lesions following cryosurgery in prostatic cancer: immunologic considerations. J Urol (1970) 1.18
Thymus-specific antigens on human thymocytes and on thymic-derived lymphocytes. Transplantation (1973) 1.10
Immunologic studies of normal, benign, and malignant human prostatic tissue. Cancer (1972) 1.09
IgE in pemphigus. Arch Dermatol (1977) 1.09
Precipitating antigens of the normal human prostate. J Reprod Fertil (1970) 1.04
Early demonstration of renal collateral arterial suppl. Am J Roentgenol Radium Ther Nucl Med (1968) 1.04
Anatomical incidence of testicular appendages. J Urol (1968) 1.03
Pemphigus-like antibodies in patients with skin burns. Vox Sang (1969) 1.02
Urethral diverticular carcinoma. Cancer (1992) 1.01
Precipitating antibody in the sera of patients treated cryosurgically for carcinoma of the prostate. Exp Med Surg (1969) 0.98
Patterns of care for carcinoma of the prostate gland: results of a national survey of 1984 and 1990. J Am Coll Surg (1995) 0.98
Serum proteins in patients with benign and malignant diseases of the prostate. Neoplasma (1971) 0.97
Blood product immunosuppression and the acquired immunodeficiency syndrome. Ann Intern Med (1986) 0.97
Odor threshold and gas-chromatographic assays of vaginal odors: changes with nitrofurazone treatment. J Pharm Sci (1970) 0.96
The accuracy of the rectal examination in the diagnosis of prostate carcinoma. N Engl J Med (1980) 0.94
In vitro effects of dichloroacetate and CO2 on hypoxic HeLa cells. Anticancer Res (2009) 0.92
Alterations of alpha2-globulin and the clinical response in patients with prostatic cancer following cryotherapy. Oncology (1975) 0.91
Localization of immunoglobulins in human prostatic tissue. J Immunol (1971) 0.90
Changes in radical prostatectomy and radiation therapy rates for African Americans and whites. J Natl Med Assoc (2000) 0.90
Tissue- and species-specific antibodies in antithymocyte globulin. Transplantation (1972) 0.90
Carcinoembryonic antigen in patients with tumors of the urogenital tract. Cancer (1972) 0.89
Effect of estrogen on tumor-associated immunity in patients with adenocarcinoma of the prostate. Cancer Res (1978) 0.89
Hormonal therapy and alteration of lymphocyte proliferation. J Lab Clin Med (1976) 0.89
Benign fibrous ureteral polyps. Urology (1987) 0.89
Immunochemical characterization of epithelial antigen(s) reactive with pemphigus-like antibodies of rabbit and human pemphigus autoantibodies. J Hyg Epidemiol Microbiol Immunol (1969) 0.87
The female prostate and prostate-specific antigen. Immunohistochemical localization, implications of this prostate marker in women and reasons for using the term "prostate" in the human female. Histol Histopathol (2000) 0.87
Condylomata acuminata: treatment by autogenous vaccine. IMJ Ill Med J (1975) 0.87
Immunobiology of the Dunning R-3327 rat prostate adenocarcinoma sublines: plasma and tumor effusion prostaglandins. Am J Reprod Immunol Microbiol (1985) 0.87
An evaluation of prostate specific antigen in prostatic cancer. J Urol (1987) 0.87
Long-term complete remission in bladder carcinoma in situ with intravesical TICE bacillus Calmette Guerin. Overview analysis of six phase II clinical trials. Urology (1991) 0.87
Renal cell carcinoma: the size variable. J Surg Oncol (1993) 0.86
Cancer, immunological surveillance, and 2 -globulin. Lancet (1972) 0.86
Prostate cancer: the stage disadvantage in the black male. J Natl Med Assoc (1991) 0.85
Leukocyte adherence inhibition and immunoreactivity in prostatic cancer. I. Identification of anti-tumour cell-mediated immunity and "blocking" factor. Eur J Cancer (1977) 0.85
Multiple primary tumors in a 72-year-old woman. J Urol (1983) 0.85
Hypertension in a child caused by a multicystic kidney. J Urol (1970) 0.85
Bacillus calmette-guerin (BCG) adjuvant therapy in stage D prostate cancer. Urology (1982) 0.85
Immunosuppressive effects of antimacrophage serum and antithymocyte serum on mouse skin allografts. J Med (1972) 0.84
Lipofuscin granules in normal, benign and malignant human prostatic tissue. Urol Res (1973) 0.84
In vivo establishment of T98G human glioblastoma. Methods Find Exp Clin Pharmacol (1999) 0.84
Immunopathologic studies of experimental pemphigus-like autoantibodies and bullous-like lesions. J Invest Dermatol (1969) 0.83
Transglutaminase: co-factor in aetiology of AIDS? Lancet (1985) 0.83
Immunosuppression of cell- and serum-medicated tumour-associated immunity in prostatic cancer by human seminal plasma. Eur J Cancer (1980) 0.82
Adjuvant immunotherapy (BCG) in stage D prostate cancer. Am J Clin Oncol (1982) 0.82
A tissue type transglutaminase in human seminal plasma. Am J Reprod Immunol (1997) 0.82
Transperitoneal vesical bivalve in repair of recurrent vesicovaginal fistula. Obstet Gynecol (1973) 0.82
An evaluation of the markers p53 and Ki-67 for their predictive value in prostate cancer. J Surg Oncol (1998) 0.82
In vivo bound immunoglobulins in the human prostate--their identification and possible significance. Z Immunitatsforsch Exp Klin Immunol (1972) 0.82
Resection of the vena cava for renal cell carcinoma: an experimental study. J Urol (1972) 0.82
Prostaglandin modulation of prostate tumor growth and metastases. Anticancer Res (1986) 0.82
A retrospective look at studies on prostate-specific antigen. Clin Chem (1985) 0.82
Zoladex: a sustained-release, monthly luteinizing hormone-releasing hormone analogue for the treatment of advanced prostate cancer. J Clin Oncol (1987) 0.81
Prognostic value of cell surface antigens using immunoperoxidase methods in bladder carcinoma. Urology (1982) 0.81
Stage IV renal cell carcinoma. J Urol (1994) 0.81
Letter: Antiepithelial antibodies: a possible clue to malignant neoplasms. Arch Dermatol (1974) 0.81
Freezing of the esophagus: histological changes and immunological response. Int Surg (1982) 0.81
Evaluation of cytologic techniques for diagnosis of prostate cancer. Urology (1983) 0.81
Fibrinolysis resistant fibrin deposits in lymph nodes with Hodgkin's disease. Thromb Haemost (1988) 0.81
Prostate cancer and the multiple primary malignant neoplasm syndrome. Prostate (1983) 0.81
Cryosurgery of the rabbit prostate. Comparison of the immune response of immature and mature bucks. Cryobiology (1974) 0.81
Autoallergy in pemphigus. Lancet (1968) 0.81
Fluorescent studies of antibodies to rabbit male urogenital tissue. Experientia (1969) 0.81
Immunologic sequelae of thermal injury. I. Frequency and relationship of epithelial antibodies to extent of burn. Clin Immunol Immunopathol (1976) 0.81
Antiepithelial antibodies in the serum of patients with benign and malignant diseases of the prostate. Z Immunitatsforsch Exp Klin Immunol (1973) 0.81
Condyloma acuminatum in a 2 1/2-year-old girl. J Urol (1983) 0.81
Giant hydronephrosis in horseshoe kidney, presenting as right upper quadrant mass and jaundice. Chic Med Sch Q (1970) 0.81
The proliferative response of hela cells to 2-deoxy-D-glucose under hypoxic or anoxic conditions: an analogue for studying some properties of in vivo solid cancers. Anticancer Res (2007) 0.81
Decreased survival of black Americans with testicular cancer. J Urol (1998) 0.80
Absorption studies on antigen(s) of the esophageal mucosa reactive with autoantibodies of pemphigus. Int Arch Allergy Appl Immunol (1968) 0.80
Bone scan as a stratification variable in advanced prostate cancer. Cancer (1991) 0.80
Carcinoembryonic antigen in the diagnosis of prostate carcinoma. Oncology (1974) 0.80
Antisense oligonucleotide intralesional therapy for human PC-3 prostate tumors carried in athymic nude mice. J Surg Oncol (1996) 0.80
Lymphocele formation after extraperitoneal pelvic lymphadenectomy: possible predisposing factors. J Urol (1986) 0.80
Suppression of tumor-associated immunity by human seminal plasma and its possible role in the natural history of prostatic cancer. Eur Urol (1980) 0.80
Modulatory effects of oestrogen on immunological responsiveness. II. Suppression of tumour-associated immunity in patients with prostatic cancer. Clin Exp Immunol (1979) 0.79
Evaluation of cellular immunologic responsiveness in the clinical management of patients with prostatic cancer. III. Inhibition of leucocyte migration. Urol Int (1976) 0.79
An immunohistologic characterization of human prostatic atypical hyperplasia. Urol Res (1990) 0.79
Anti-tissue IgG antibodies and deficiency of IgA. Vox Sang (1972) 0.79
Androgens and oestrogens may modulate the growth and function of lymphoid organs. J Immunol (1984) 0.79
Selective deficiency of IgA. Lancet (1971) 0.79
Enhanced expression of bcl-2 following antisense oligonucleotide mediated growth factor deprivation. Med Oncol (1997) 0.79
Immunotherapy for prostatic cancer. Previous and prospective considerations. Oncology (1975) 0.79
Normoxic or hypoxic CD44/CD41 a₂ B₁ integrin-positive prostate PC3 cell side fractions and cancer stem cells. Med Oncol (2013) 0.79
Neuromuscular dysfunctions of the external urinary sphincter. IMJ Ill Med J (1974) 0.79
Retinal artery changes correlated with other hypertensive parameters in a coronary heart disease case-history study. Br Heart J (1968) 0.79
Application of immunohistologic staining to develop a malignant index to aid in distinguishing benign from malignant prostatic tissue. Prostate (1989) 0.79